TABLE 1.

Summary of Efficacy and Safety of Canagliflozin as Add-On to Metformin, Metformin Plus Sulfonylurea, and Insulin in Patients With Type 2 Diabetes Over 52 Weeks (3,30–33,50,53)

Canagliflozin as:
Add-on to METAdd-on to MET + SUAdd-on to insulin
Changes in key efficacy parameters
Body weight (kg)GLIMPBOPBO
 Baseline: 86.6 Baseline: 90.8 Baseline: 97.7
 Change: +1.0% (+0.7) Change: –0.9% (–1.0) Change: +0.1% (+0.1)
CANA 100 mgCANA 100 mgCANA 100 mg
 Baseline: 86.8 Baseline: 93.5 Baseline: 96.9
 Change: –4.2% (–3.7) Change: –2.2% (–2.0) Change: –2.4% (–2.3)
CANA 300 mgCANA 300 mgCANA 300 mg
 Baseline: 86.6 Baseline: 93.5 Baseline: 96.7
 Change: –4.7% (–4.0) Change: –3.2% (–3.1) Change: –3.1% (–3.0)
SITASITA
 Baseline: 87.6 Baseline: 89.6
 Change: –1.3% (–1.2) Change: +0.3% (+0.1)
CANA 100 mgCANA 300 mg
 Baseline: 88.7 Baseline: 87.6
 Change: –3.8% (–3.3) Change: –2.5% (–2.3)
CANA 300 mg
 Baseline: 85.4
 Change: –4.2% (–3.7)
  • CANA, canagliflozin; GLIM, glimepiride; MET, metformin; PBO, placebo; SITA, sitagliptin; SU, sulfonylurea.